TG Therapeutics Inc (TGTX)

Exchange
NASDAQ
Symbol
TGTX
Sector
Life Sciences
Industry
Pharmaceutical Preparations
Description
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Country
USA

Stock price

At close: December 20, 2024

  • Open
    30.60
  • High
    32.63
  • Low
    30.50
  • Close
    32.20
  • Volume
    2,790,110

Financial ratios

Sep 30, 2024

Activity ratios
Inventory turnover
2.09
Receivables turnover
2.27
Payables turnover
—
Working capital turnover
0.58
Days of inventory on hand (DOH)
174.33
Days of sales outstanding (DSO)
161.00
Number of days of payables
—
Fixed asset turnover
—
Total asset turnover
0.45
 Liquidity ratios
Current ratio
4.59
Quick ratio
3.65
Cash ratio
2.73
Cash conversion cycle
335.34
 Solvency ratios
Debt-to-assets ratio
0.42
Debt-to-capital ratio
0.56
Debt-to-equity ratio
1.27
Financial leverage ratio
3.05
Interest coverage
0.09
 Profitability ratios
Gross profit margin
32.43%
Operating profit margin
-0.19%
Pretax margin
-5.29%
Net profit margin
-5.47%
Operating return on assets (Operating ROA)
-0.09%
Return on assets (ROA)
-2.45%
Return on total capital
0.09%
Return on equity (ROE)
-7.48%